A Study to Assess Real-World Use, Safety, and Effectiveness of Oral Upadacitinib in Adult and Adolescent (>=12 Years Old) Participants With Atopic Dermatitis
- Conditions
- Atopic Dermatitis
- Registration Number
- NCT05081557
- Lead Sponsor
- AbbVie
- Brief Summary
Atopic dermatitis (AD; also known as atopic eczema) is an inflammatory skin disease. The safety and effectiveness of upadacitinib for AD has been well-documented in previous studies, however, important information is missing on the use patterns and outcomes with upadacitinib in a real-world setting. Therefore, the purpose of this observational study is to help inform real-world usage patterns regarding the safety and effectiveness and duration of response of upadacitinib in adolescent and adult AD participants \>=12 years old in the real-world setting.
Upadacitinib is an approved drug being developed for the treatment of AD. Around 975 adolescent and adult participants who are prescribed upadacitinib for the treatment of AD in routine clinical practice will be enrolled worldwide.
Participants will receive oral upadacitinib as prescribed by their physician. Data from these participants will be collected for approximately 2 years.
There will be no additional burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the course of the study at a hospital or clinic and will be asked to provide additional information by questionnaire at each visit.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 873
- Physician confirmed diagnosis of atopic dermatitis (AD) or atopic eczema at baseline.
- Symptom onset >=1-year prior to baseline.
- Initiation of upadacitinib treatment for AD is indicated and prescribed per local label.
- The decision to prescribe UPA is made prior to and independently of study participation.
- Medical and medication history available for previous 6 months.
- Participants who can understand the questionnaires, with parental support as required for adolescents.
- Participants who are able to understand and communicate with the investigator and comply with the requirements of the study.
- Participants who are willing and able to participate in the collection of patient-reported data via cloud-based mobile application using a smart device (i.e., tablet).
- Participants who are willing and able to complete the patient-reported questionnaires.
- Participants who are currently participating in interventional research (not including non-interventional study, post-marketing observational study, or registry participation).
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Upadacitinib (UPA) Utilization Patterns Up to Approximately 24 Months UPA utilization patterns will be achieved by (i) providing descriptive statistics of patient demographics and disease characteristics for patients who starting UPA 15 mg at baseline and patients who starting UPA 30 mg at baseline, respectively; (ii) calculating number and proportion of patients with different UPA and concomitant therapy changes throughout the observation period, and the rationale for any changes.
Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) 0/1 Month 4 vIGA-AD is a validated assessment instrument used in clinical studies to rate the severity of AD globally. A 5-point scale is used to measure the severity of disease at the time of the investigator's evaluation of the participant ranging from 0 - Clear (no inflammatory signs of atopic dermatitis (no erythema, no induration/papulation, no lichenification, no oozing/crusting). Post-inflammatory hyperpigmentation and/or hypopigmentation may be present.) to 4 - Severe (marked erythema (deep or bright red), marked induration/papulation, and/or marked lichenification.
vIGA-AD 0/1 Among Participants Who Achieved vIGA-AD 0/1 at Month 4 Month 24 vIGA-AD is a validated assessment instrument used in clinical studies to rate the severity of AD globally. A 5-point scale is used to measure the severity of disease at the time of the investigator's evaluation of the participant ranging from 0 - Clear (no inflammatory signs of atopic dermatitis (no erythema, no induration/papulation, no lichenification, no oozing/crusting). Post-inflammatory hyperpigmentation and/or hypopigmentation may be present.) to 4 - Severe (marked erythema (deep or bright red), marked induration/papulation, and/or marked lichenification.
- Secondary Outcome Measures
Name Time Method Modification of UPA or Concomitant AD Therapy and Associated Timing, Reasons Month 24 This includes UPA dose change, temporary or permanent discontinuation, switching, add or remove TCS.
Percentage of Participants Achieving EASI <=1 Up to Approximately 24 Months The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. Four AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) are each assessed for severity by the investigator on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. In each body region, the area is expressed as 0, 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%). The EASI score ranges from 0-72 points with an MCID of 6.6 points. Published score bands: clear (0), almost clear (0.1-1.0), mild AD (1.1-7.0), moderate AD (7.1-21.0), severe AD (21.1-50.0), very severe AD (50.1-72.0).
Percentage of Participants Achieving WP-NRS <=3 Up to Approximately 24 Months WP-NRS is a validated single self-reported item designed to measure peak pruritus, or 'worst' itch, over the previous 24 hours with a higher score denoting worse itch.
Percentage of Participants Achieving Patient Oriented Eczema Measurement (POEM) Score <=2 Up to Approximately 24 Months The POEM is a 7-item, validated questionnaire used in clinical practice and clinical trials to assess disease symptoms in both children and adults. Subjects respond to 7 items, including dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping, each scored on a 5-point scale based on frequency over the previous week: 0 = no days, 1 = 1 to 2 days, 2 = 3 to 4 days, 3 = 5 to 6 days, and 4 = all days. Item scores (0 to 4) are added to provide a total score range of 0 to 28. The total score reflects disease-related morbidity, and differentiates between "clear/almost clear" (0-2 points), "mild" (3-7 points), "moderate" (8-16 points), "severe" (17-24 points) and "very severe" (25-28 points) AD. A change in POEM score of 3.4 points is considered the MCID.
Percentage of Participants who are "Extremely Satisfied" or "Very Satisfied" with their AD Treatment using the Patient Global Impression of Treatment for Atopic Dermatitis (PGIT-AD) Up to Approximately 24 Months PGIT-AD is a single item patient self-administered instrument designed to assess patient satisfaction or dissatisfaction with their current treatment for atopic dermatitis based on the following question: "Overall, how satisfied or dissatisfied are you with your current treatment for atopic dermatitis?". Response options range from 1 (extremely dissatisfied) to 7 (extremely satisfied).
Percentage of Participants Achieving vIGA-AD 0/1 Among Participants Who Achieved vIGA-AD at Month 4 Up to Approximately 24 Months (Excluding Month 24 - Primary Outcome) vIGA-AD is a validated assessment instrument used in clinical studies to rate the severity of AD globally. A 5-point scale is used to measure the severity of disease at the time of the investigator's evaluation of the participant ranging from 0 - Clear (no inflammatory signs of atopic dermatitis (no erythema, no induration/papulation, no lichenification, no oozing/crusting). Post-inflammatory hyperpigmentation and/or hypopigmentation may be present.) to 4 - Severe (marked erythema (deep or bright red), marked induration/papulation, and/or marked lichenification.
Percentage of Participants Achieving EASI <=5.9 Up to Approximately 24 Months The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. Four AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) are each assessed for severity by the investigator on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. In each body region, the area is expressed as 0, 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%). The EASI score ranges from 0-72 points with an MCID of 6.6 points. Published score bands: clear (0), almost clear (0.1-1.0), mild AD (1.1-7.0), moderate AD (7.1-21.0), severe AD (21.1-50.0), very severe AD (50.1-72.0).
Percentage of Participants Achieving EASI <=7 Up to Approximately 24 Months The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. Four AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) are each assessed for severity by the investigator on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. In each body region, the area is expressed as 0, 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%). The EASI score ranges from 0-72 points with an MCID of 6.6 points. Published score bands: clear (0), almost clear (0.1-1.0), mild AD (1.1-7.0), moderate AD (7.1-21.0), severe AD (21.1-50.0), very severe AD (50.1-72.0).
Percentage of Participants Achieving Dermatology Life Quality Index (DLQI) Score of 0/1 Up to Approximately 24 Months DLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of AD disease symptoms and treatment on health-related quality of life (HRQoL). It consists of 10 questions assessing impact of skin diseases on different aspects of subject's QoL over the prior week. Each item is scored on a 4-point scale: 0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much. Item scores (0 to 3) are added to provide a total score range of 0 to 30. Higher scores indicate greater impairment of HRQoL.
Percentage of Participants Remaining on Upadacitinib Once Daily Up to Approximately 24 Months Percentage of participants remaining on upadacitinib once daily at all applicable time points.
Percentage of Participants Achieving EASI 100 Among Participants Who Achieved EASI 100 at Month 4 Up to Approximately 24 months The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. Four AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) are each assessed for severity by the investigator on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. In each body region, the area is expressed as 0, 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%). The EASI score ranges from 0-72 points with an MCID of 6.6 points. Published score bands: clear (0), almost clear (0.1-1.0), mild AD (1.1-7.0), moderate AD (7.1-21.0), severe AD (21.1-50.0), very severe AD (50.1-72.0).
Percentage of Participants Achieving Eczema Area and Severity Index (EASI) 75 Up to Approximately 24 months The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. Four AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) are each assessed for severity by the investigator on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. In each body region, the area is expressed as 0, 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%). The EASI score ranges from 0-72 points with an MCID of 6.6 points. Published score bands: clear (0), almost clear (0.1-1.0), mild AD (1.1-7.0), moderate AD (7.1-21.0), severe AD (21.1-50.0), very severe AD (50.1-72.0).
Percentage of Participants Achieving Worst Pruritus Numerical Rating Scale (WP-NRS) 0/1 Up to Approximately 24 Months Worst Pruritus NRS is a validated single self-reported item designed to measure peak pruritus, or 'worst' itch, over the previous 24 hours with a higher score denoting worse itch.
Percentage of Participants Achieving WP-NRS reduction >=4 Up to Approximately 24 Months WP-NRS is a validated single self-reported item designed to measure peak pruritus, or 'worst' itch, over the previous 24 hours with a higher score denoting worse itch.
Percentage of Participants Achieving POEM <=7 Up to Approximately 24 Months The POEM is a 7-item, validated questionnaire used in clinical practice and clinical trials to assess disease symptoms in both children and adults. Subjects respond to 7 items, including dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping, each scored on a 5-point scale based on frequency over the previous week: 0 = no days, 1 = 1 to 2 days, 2 = 3 to 4 days, 3 = 5 to 6 days, and 4 = all days. Item scores (0 to 4) are added to provide a total score range of 0 to 28. The total score reflects disease-related morbidity, and differentiates between "clear/almost clear" (0-2 points), "mild" (3-7 points), "moderate" (8-16 points), "severe" (17-24 points) and "very severe" (25-28 points) AD. A change in POEM score of 3.4 points is considered the MCID
Percentage of Participants Achieving EASI 90 Up to Approximately 24 Months The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. Four AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) are each assessed for severity by the investigator on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. In each body region, the area is expressed as 0, 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%). The EASI score ranges from 0-72 points with an MCID of 6.6 points. Published score bands: clear (0), almost clear (0.1-1.0), mild AD (1.1-7.0), moderate AD (7.1-21.0), severe AD (21.1-50.0), very severe AD (50.1-72.0).
Percentage of Participants Achieving EASI 100 Up to Approximately 24 Months The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. Four AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) are each assessed for severity by the investigator on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. In each body region, the area is expressed as 0, 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%). The EASI score ranges from 0-72 points with an MCID of 6.6 points. Published score bands: clear (0), almost clear (0.1-1.0), mild AD (1.1-7.0), moderate AD (7.1-21.0), severe AD (21.1-50.0), very severe AD (50.1-72.0).
Percentage of Participants Achieving vIGA-AD 0/1 Up to Approximately 24 Months (Excluding Month 4 - Primary Outcome) vIGA-AD is a validated assessment instrument used in clinical studies to rate the severity of AD globally. A 5-point scale is used to measure the severity of disease at the time of the investigator's evaluation of the participant ranging from 0 - Clear (no inflammatory signs of atopic dermatitis (no erythema, no induration/papulation, no lichenification, no oozing/crusting). Post-inflammatory hyperpigmentation and/or hypopigmentation may be present.) to 4 - Severe (marked erythema (deep or bright red), marked induration/papulation, and/or marked lichenification.
Percentage of Participants Achieving DLQI Score <=5 Up to Approximately 24 Months DLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of AD disease symptoms and treatment on health-related quality of life (HRQoL). It consists of 10 questions assessing impact of skin diseases on different aspects of subject's QoL over the prior week. Each item is scored on a 4-point scale: 0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much. Item scores (0 to 3) are added to provide a total score range of 0 to 30. Higher scores indicate greater impairment of HRQoL.
Percentage of Participants Achieving Atopic Dermatitis Control Tool (ADCT) <7 (control) Up to Approximately 24 Months The ADCT is a validated patient self-administered instrument designed to assess AD control status in adult and adolescent patients (12 years and older). Six AD symptoms and impacts are evaluated over the past week including overall severity of symptoms, days with intense episodes of itching, intensity of bother, problem with sleep, impact on daily activities, and impact on mood or emotions. Each item is scored 0-4. The sum of the 6 item scores form the ADCT total score (range 0-24). A higher score indicates lower AD control. A score of ≥7 indicates that the patient is not in control. The threshold for meaningful within-person change is estimated to be 5 points.
Change from Baseline in the Number of AD-Related Physician Office or Hospital Visits Up to Approximately 24 Months Participants are asked the number of AD-related physician office visits in the previous 6 months and the number of AD-related hospital visits in the previous 6 months.
Percentage of Participants Achieving POEM Reduction >=4 Up to Approximately 24 Months The POEM is a 7-item, validated questionnaire used in clinical practice and clinical trials to assess disease symptoms in both children and adults. Subjects respond to 7 items, including dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping, each scored on a 5-point scale based on frequency over the previous week: 0 = no days, 1 = 1 to 2 days, 2 = 3 to 4 days, 3 = 5 to 6 days, and 4 = all days. Item scores (0 to 4) are added to provide a total score range of 0 to 28. The total score reflects disease-related morbidity, and differentiates between "clear/almost clear" (0-2 points), "mild" (3-7 points), "moderate" (8-16 points), "severe" (17-24 points) and "very severe" (25-28 points) AD. A change in POEM score of 3.4 points is considered the MCID
Percentage of Participants Achieving DLQI Score of 0/1 Among Participants Achieving DLQI Score of 0/1 at Month 4 Up to Approximately 24 Months DLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of AD disease symptoms and treatment on health-related quality of life (HRQoL). It consists of 10 questions assessing impact of skin diseases on different aspects of subject's QoL over the prior week. Each item is scored on a 4-point scale: 0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much. Item scores (0 to 3) are added to provide a total score range of 0 to 30. Higher scores indicate greater impairment of HRQoL.
Absolute Score and Change from Baseline in POEM Up to Approximately 24 Months The POEM is a 7-item, validated questionnaire used in clinical practice and clinical trials to assess disease symptoms in both children and adults. Subjects respond to 7 items, including dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping, each scored on a 5-point scale based on frequency over the previous week: 0 = no days, 1 = 1 to 2 days, 2 = 3 to 4 days, 3 = 5 to 6 days, and 4 = all days. Item scores (0 to 4) are added to provide a total score range of 0 to 28. The total score reflects disease-related morbidity, and differentiates between "clear/almost clear" (0-2 points), "mild" (3-7 points), "moderate" (8-16 points), "severe" (17-24 points) and "very severe" (25-28 points) AD. A change in POEM score of 3.4 points is considered the MCID.
Absolute Score and Change from Baseline in Work Productivity and Activity Impairment Index for Atopic Dermatitis (WPAI-AD) Up to Approximately 24 Months The Work Productivity and Activity Impairment Index for Atopic Dermatitis (WPAI-AD) is a validated instrument used to measure loss of productivity at work and impairment in daily activities over the past 7 days. The questionnaire includes four items: absenteeism, presenteeism, overall work impairment, and activity impairment, that range from 0% to 100%, with higher values indicating greater impairment. While absenteeism represents the percentage of work time missed due to AD, presenteeism represents the percentage of impairment while at work due to AD. Overall work impairment represents the total percentage of work time missed due to either absenteeism or presenteeism (since those are mutually exclusive). Activity impairment represents the percentage of impairment during daily activities other than work. The 4 items are all evaluated using an 11-point Likert-type scale from 0 (no effect) to 10 (completely prevented), and the scores are multiplied by ten to arrive at a percentage.
Percentage of Participants Achieving Treatment Target WP-NRS <=4 Up to Approximately 24 Months WP-NRS is a validated single self-reported item designed to measure peak pruritus, or 'worst' itch, over the previous 24 hours with a higher score denoting worse itch.
Time to Achieve EASI 75 Up to Approximately 24 months The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. Four AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) are each assessed for severity by the investigator on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. In each body region, the area is expressed as 0, 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%). The EASI score ranges from 0-72 points with an MCID of 6.6 points. Published score bands: clear (0), almost clear (0.1-1.0), mild AD (1.1-7.0), moderate AD (7.1-21.0), severe AD (21.1-50.0), very severe AD (50.1-72.0).
Time-Weighted EASI Score Up to Approximately 24 Months The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. Four AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) are each assessed for severity by the investigator on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. In each body region, the area is expressed as 0, 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%). The EASI score ranges from 0-72 points with an MCID of 6.6 points. Published score bands: clear (0), almost clear (0.1-1.0), mild AD (1.1-7.0), moderate AD (7.1-21.0), severe AD (21.1-50.0), very severe AD (50.1-72.0).
Time-Weighted WP-NRS Score Up to Approximately 24 Months WP-NRS is a validated single self-reported item designed to measure peak pruritus, or 'worst' itch, over the previous 24 hours with a higher score denoting worse itch.
Percentage of Participants Achieving DLQI reduction >=4 Up to Approximately 24 Months DLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of AD disease symptoms and treatment on health-related quality of life (HRQoL). It consists of 10 questions assessing impact of skin diseases on different aspects of subject's QoL over the prior week. Each item is scored on a 4-point scale: 0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much. Item scores (0 to 3) are added to provide a total score range of 0 to 30. Higher scores indicate greater impairment of HRQoL.
Percentage of Participants Achieving ADCT reduction >=5 Up to approximately 24 Months The ADCT is a validated patient self-administered instrument designed to assess AD control status in adult and adolescent patients (12 years and older). Six AD symptoms and impacts are evaluated over the past week including overall severity of symptoms, days with intense episodes of itching, intensity of bother, problem with sleep, impact on daily activities, and impact on mood or emotions. Each item is scored 0-4. The sum of the 6 item scores form the ADCT total score (range 0-24). A higher score indicates lower AD control. A score of ≥7 indicates that the patient is not in control. The threshold for meaningful within-person change is estimated to be 5 points.
Percentage of Participants Achieving EASI 75 Among Participants Who Achieved EASI 75 at Month 4 Up to Approximately 24 months The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. Four AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) are each assessed for severity by the investigator on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. In each body region, the area is expressed as 0, 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%). The EASI score ranges from 0-72 points with an MCID of 6.6 points. Published score bands: clear (0), almost clear (0.1-1.0), mild AD (1.1-7.0), moderate AD (7.1-21.0), severe AD (21.1-50.0), very severe AD (50.1-72.0).
Absolute Score and Change from Baseline in DLQI Up to Approximately 24 Months DLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of AD disease symptoms and treatment on health-related quality of life (HRQoL). It consists of 10 questions assessing impact of skin diseases on different aspects of subject's QoL over the prior week. Each item is scored on a 4-point scale: 0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much. Item scores (0 to 3) are added to provide a total score range of 0 to 30. Higher scores indicate greater impairment of HRQoL.
Time to Achieve EASI 100 Up to Approximately 24 months The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. Four AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) are each assessed for severity by the investigator on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. In each body region, the area is expressed as 0, 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%). The EASI score ranges from 0-72 points with an MCID of 6.6 points. Published score bands: clear (0), almost clear (0.1-1.0), mild AD (1.1-7.0), moderate AD (7.1-21.0), severe AD (21.1-50.0), very severe AD (50.1-72.0).
Time to Achieve POEM <=2 Up to Approximately 24 Months The POEM is a 7-item, validated questionnaire used in clinical practice and clinical trials to assess disease symptoms in both children and adults. Subjects respond to 7 items, including dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping, each scored on a 5-point scale based on frequency over the previous week: 0 = no days, 1 = 1 to 2 days, 2 = 3 to 4 days, 3 = 5 to 6 days, and 4 = all days. Item scores (0 to 4) are added to provide a total score range of 0 to 28. The total score reflects disease-related morbidity, and differentiates between "clear/almost clear" (0-2 points), "mild" (3-7 points), "moderate" (8-16 points), "severe" (17-24 points) and "very severe" (25-28 points) AD. A change in POEM score of 3.4 points is considered the MCID.
Time to Achieve ADCT <7 Up to Approximately 24 Months The ADCT is a validated patient self-administered instrument designed to assess AD control status in adult and adolescent patients (12 years and older). Six AD symptoms and impacts are evaluated over the past week including overall severity of symptoms, days with intense episodes of itching, intensity of bother, problem with sleep, impact on daily activities, and impact on mood or emotions. Each item is scored 0-4. The sum of the 6 item scores form the ADCT total score (range 0-24). A higher score indicates lower AD control. A score of ≥7 indicates that the patient is not in control. The threshold for meaningful within-person change is estimated to be 5 points.
Percentage of Participants Achieving EASI 90 Among Participants Who Achieved EASI 90 at Month 4 Up to Approximately 24 months The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. Four AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) are each assessed for severity by the investigator on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. In each body region, the area is expressed as 0, 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%). The EASI score ranges from 0-72 points with an MCID of 6.6 points. Published score bands: clear (0), almost clear (0.1-1.0), mild AD (1.1-7.0), moderate AD (7.1-21.0), severe AD (21.1-50.0), very severe AD (50.1-72.0).
Percentage of Participants Achieving WP-NRS 0/1 Among Participants Who Achieved WP-NRS 0/1 at Month 4 Up to Approximately 24 Months WP-NRS is a validated single self-reported item designed to measure peak pruritus, or 'worst' itch, over the previous 24 hours with a higher score denoting worse itch.
Absolute Score and Change from Baseline in ADCT Up to Approximately 24 months The ADCT is a validated patient self-administered instrument designed to assess AD control status in adult and adolescent patients (12 years and older). Six AD symptoms and impacts are evaluated over the past week including overall severity of symptoms, days with intense episodes of itching, intensity of bother, problem with sleep, impact on daily activities, and impact on mood or emotions. Each item is scored 0-4. The sum of the 6 item scores form the ADCT total score (range 0-24). A higher score indicates lower AD control. A score of ≥7 indicates that the patient is not in control. The threshold for meaningful within-person change is estimated to be 5 points.
Time to Achieve EASI 90 Up to Approximately 24 months The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. Four AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) are each assessed for severity by the investigator on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. In each body region, the area is expressed as 0, 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%). The EASI score ranges from 0-72 points with an MCID of 6.6 points. Published score bands: clear (0), almost clear (0.1-1.0), mild AD (1.1-7.0), moderate AD (7.1-21.0), severe AD (21.1-50.0), very severe AD (50.1-72.0).
Time to Achieve vIGA-AD 0/1 Up to Approximately 24 Months vIGA-AD is a validated assessment instrument used in clinical studies to rate the severity of AD globally. A 5-point scale is used to measure the severity of disease at the time of the investigator's evaluation of the participant ranging from 0 - Clear (no inflammatory signs of atopic dermatitis (no erythema, no induration/papulation, no lichenification, no oozing/crusting). Post-inflammatory hyperpigmentation and/or hypopigmentation may be present.) to 4 - Severe (marked erythema (deep or bright red), marked induration/papulation, and/or marked lichenification.
Time-Weighted vIGA-AD Score Up to Approximately 24 Months vIGA-AD is a validated assessment instrument used in clinical studies to rate the severity of AD globally. A 5-point scale is used to measure the severity of disease at the time of the investigator's evaluation of the participant ranging from 0 - Clear (no inflammatory signs of atopic dermatitis (no erythema, no induration/papulation, no lichenification, no oozing/crusting). Post-inflammatory hyperpigmentation and/or hypopigmentation may be present.) to 4 - Severe (marked erythema (deep or bright red), marked induration/papulation, and/or marked lichenification.
Percentage of Participants Achieving Combined Treatment Targets of EASI <8, DLQI <=5, and WP-NRS <=4 Up to Approximately 24 Months EASI is a validated measure used to assess the severity and extent of AD. Four AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) are each assessed for severity by the investigator on a scale of "0" (absent) through "3" (severe). DLQI is a 10-item, validated questionnaire to assess the impact of AD disease symptoms and treatment on HRQoL. It consists of 10 questions assessing impact of skin diseases on different aspects of subject's QoL over the prior week. Each item is scored on a 4-point scale: 0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much. Item scores (0 to 3) are added to provide a total score range of 0 to 30. Higher scores indicate greater impairment of HRQoL. WP-NRS is a validated single self-reported item designed to measure peak pruritus, or 'worst' itch, over the previous 24 hours.
Percentage of Participants Achieving ADCT Reduction <7 Among Participants Who Achieved ADCT Reduction <7 at Month 4 Up to approximately 24 Months The ADCT is a validated patient self-administered instrument designed to assess AD control status in adult and adolescent patients (12 years and older). Six AD symptoms and impacts are evaluated over the past week including overall severity of symptoms, days with intense episodes of itching, intensity of bother, problem with sleep, impact on daily activities, and impact on mood or emotions. Each item is scored 0-4. The sum of the 6 item scores form the ADCT total score (range 0-24). A higher score indicates lower AD control. A score of ≥7 indicates that the patient is not in control. The threshold for meaningful within-person change is estimated to be 5 points.
Absolute Score and Change from Baseline in Body Surface Area (BSA) Up to Approximately 24 Months The investigator selects the participant's right or left hand as the measuring device. For purposes of clinical estimation, the total surface of the palm plus five digits is assumed to be approximately equivalent to 1%. Measurement of the total area of involvement by the investigator is aided by imagining if scattered plaques were moved so that they were next to each other and then estimating the total area involved. Published score bands: 0% (clear), 0.1-15.9% (mild), 16.0-39.9% (moderate), 40-100% (severe).
Absolute Score and Change from Baseline in WP-NRS Up to Approximately 24 Months WP-NRS is a validated single self-reported item designed to measure peak pruritus, or 'worst' itch, over the previous 24 hours with a higher score denoting worse itch.
Absolute Score and Change from Baseline in PGIT-AD Up to Approximately 24 Months PGIT-AD is a single item patient self-administered instrument designed to assess patient satisfaction or dissatisfaction with their current treatment for atopic dermatitis based on the following question: "Overall, how satisfied or dissatisfied are you with your current treatment for atopic dermatitis?". Response options range from 1 (extremely dissatisfied) to 7 (extremely satisfied).
Time to Achieve WP-NRS 0/1 Up to Approximately 24 Months WP-NRS is a validated single self-reported item designed to measure peak pruritus, or 'worst' itch, over the previous 24 hours with a higher score denoting worse itch.
Absolute Score and Change from Baseline in EASI Up to Approximately 24 months The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. Four AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) are each assessed for severity by the investigator on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. In each body region, the area is expressed as 0, 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%). The EASI score ranges from 0-72 points with an MCID of 6.6 points. Published score bands: clear (0), almost clear (0.1-1.0), mild AD (1.1-7.0), moderate AD (7.1-21.0), severe AD (21.1-50.0), very severe AD (50.1-72.0).
Absolute Score and Change from Baseline in vIGA-AD Up to Approximately 24 months vIGA-AD is a validated assessment instrument used in clinical studies to rate the severity of AD globally. A 5-point scale is used to measure the severity of disease at the time of the investigator's evaluation of the participant ranging from 0 - Clear (no inflammatory signs of atopic dermatitis (no erythema, no induration/papulation, no lichenification, no oozing/crusting). Post-inflammatory hyperpigmentation and/or hypopigmentation may be present.) to 4 - Severe (marked erythema (deep or bright red), marked induration/papulation, and/or marked lichenification.
Change from Baseline in Flare Frequency and Duration Up to Approximately 24 Months Participants are asked to provide the number of flares in the previous 6 months, and the average duration of flares in the previous 6 months. Participants are asked if currently experiencing an atopic dermatitis flare. Flare is defined as a sudden worsening of AD requiring treatment escalation and/or additional medical advice.
Time to Achieve DLQI Score of 0/1 Up to Approximately 24 Months DLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of AD disease symptoms and treatment on health-related quality of life (HRQoL). It consists of 10 questions assessing impact of skin diseases on different aspects of subject's QoL over the prior week. Each item is scored on a 4-point scale: 0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much. Item scores (0 to 3) are added to provide a total score range of 0 to 30. Higher scores indicate greater impairment of HRQoL.
Time-Weighted DLQI Score Up to Approximately 24 Months DLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of AD disease symptoms and treatment on health-related quality of life (HRQoL). It consists of 10 questions assessing impact of skin diseases on different aspects of subject's QoL over the prior week. Each item is scored on a 4-point scale: 0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much. Item scores (0 to 3) are added to provide a total score range of 0 to 30. Higher scores indicate greater impairment of HRQoL.
Percentage of Participants Achieving Treatment Target EASI <8 Up to Approximately 24 Months The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. Four AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) are each assessed for severity by the investigator on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. In each body region, the area is expressed as 0, 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%). The EASI score ranges from 0-72 points with an MCID of 6.6 points. Published score bands: clear (0), almost clear (0.1-1.0), mild AD (1.1-7.0), moderate AD (7.1-21.0), severe AD (21.1-50.0), very severe AD (50.1-72.0).
Percentage of Participants Achieving Treatment Target DLQI <=5 Up to Approximately 24 Months DLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of AD disease symptoms and treatment on health-related quality of life (HRQoL). It consists of 10 questions assessing impact of skin diseases on different aspects of subject's QoL over the prior week. Each item is scored on a 4-point scale: 0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much. Item scores (0 to 3) are added to provide a total score range of 0 to 30. Higher scores indicate greater impairment of HRQoL.
Trial Locations
- Locations (140)
National Research Center Institute of Immunology of the FMBA of Russia /ID# 245221
🇷🇺Moscow, Moskva, Russian Federation
LLC Medical Center ABC of Health /ID# 244816
🇷🇺Kazan, Tatarstan, Respublika, Russian Federation
Hospital Universitario Austral /ID# 241607
🇦🇷Pilar, Buenos Aires, Argentina
Buenos Aires Skin /ID# 241606
🇦🇷Ciudad Autonoma de Buenos Aire, Ciudad Autonoma De Buenos Aires, Argentina
CEDIC Centro de Investigaciones Clinicas /ID# 241605
🇦🇷Ciudad Autonoma de Buenos Aire, Ciudad Autonoma De Buenos Aires, Argentina
Instituto de Neumonologia y Dermatologia /ID# 241604
🇦🇷Ciudad Autonoma de Buenos Aire, Ciudad Autonoma De Buenos Aires, Argentina
Centro Respiratorio Infantil /ID# 241609
🇦🇷Rosario, Santa Fe, Argentina
Hospital Italiano /ID# 241608
🇦🇷Caba, Argentina
Kingsway Dermatology & Aesthetics /ID# 242276
🇦🇺Miranda, New South Wales, Australia
Veracity Clinical Research /ID# 242275
🇦🇺Woolloongabba, Queensland, Australia
Flinders Medical Centre /ID# 242162
🇦🇺Bedford, Park, South Australia, Australia
Sinclair Dermatology - Melbourne /ID# 242163
🇦🇺East Melbourne, Victoria, Australia
Burswood Dermatology /ID# 243767
🇦🇺Victoria Park, Western Australia, Australia
Sydney Skin /ID# 242277
🇦🇺Newtown, Australia
Ordensklinikum Linz GmbH Elisabethinen /ID# 246565
🇦🇹Linz, Oberoesterreich, Austria
Klinikum Wels-Grieskirchen GmbH /ID# 247369
🇦🇹Wels, Oberoesterreich, Austria
Dr. Achim Schneeberger /ID# 247370
🇦🇹Nenzing, Vorarlberg, Austria
Medizin am Hauptbahnhof /ID# 246567
🇦🇹Vienna, Wien, Austria
EZW HAUT Entzuendungszentrum Wien /ID# 246566
🇦🇹Vienna, Wien, Austria
Rejuvenation Dermatology - Edmonton Downtown /ID# 240377
🇨🇦Edmonton, Alberta, Canada
Winnipeg Clinic /ID# 239603
🇨🇦Winnipeg, Manitoba, Canada
Dr. Irina Turchin PC Inc. /ID# 240358
🇨🇦Fredericton, New Brunswick, Canada
Karma Clinical Trials /ID# 239602
🇨🇦St. John's, Newfoundland and Labrador, Canada
NewLab Clinical Research Inc. /ID# 239600
🇨🇦St. John's, Newfoundland and Labrador, Canada
Dr Melinda Gooderham Medicine Profession /ID# 239745
🇨🇦Cobourg, Ontario, Canada
Lima's Excellence in Allergy and Dermatology Research Inc /ID# 239854
🇨🇦Hamilton, Ontario, Canada
Lynde Institute for Dermatology /ID# 240025
🇨🇦Markham, Ontario, Canada
Gordon Sussman Medicine Professional Corporation /ID# 243383
🇨🇦North York, Ontario, Canada
JRB Research /ID# 241862
🇨🇦Ottawa, Ontario, Canada
Dr. Michael Cecchini Medicine Professional Corporation /ID# 239605
🇨🇦Richmond Hill, Ontario, Canada
Dr. Lyne Giroux Medicine Professional Corporation /ID# 240084
🇨🇦Sudbury, Ontario, Canada
North York Research Inc /ID# 253191
🇨🇦Toronto, Ontario, Canada
Canadian Dermatology Centre /ID# 240585
🇨🇦Toronto, Ontario, Canada
Centricity Research - Toronto Dermatology /ID# 241019
🇨🇦Toronto, Ontario, Canada
Dr Maksym Breslavets Medicine Professional Corporation /ID# 239741
🇨🇦Whitby, Ontario, Canada
Clinique D /ID# 239601
🇨🇦Laval, Quebec, Canada
Roula Rassi MD Inc /ID# 252562
🇨🇦Laval, Quebec, Canada
Dre Angelique Gagne-Henley M.D. inc. /ID# 239604
🇨🇦Saint-Jerome, Quebec, Canada
Clinique de Dermatologie du Haut-Richelieu /ID# 239742
🇨🇦St-Jean Sur Le Richelieu, Quebec, Canada
Nemocnice Ceske Budejovice a.s. /ID# 246479
🇨🇿Ceske Budejovice, Praha 17, Czechia
Nemocnice Na Bulovce /ID# 246482
🇨🇿Prague, Stredocesky Kraj, Czechia
Fakultni nemocnice Olomouc /ID# 251177
🇨🇿Olomouc, Czechia
Duplicate_Fakultni Nemocnice v Motole /ID# 246480
🇨🇿Prague, Czechia
Fakultni nemocnice Kralovske Vinohrady /ID# 250792
🇨🇿Praha, Czechia
Olympion General Clinic /ID# 261694
🇬🇷Patras, Achaia, Greece
Hygeia Hospital /ID# 254188
🇬🇷Amaroussio, Attiki, Greece
401 GSNA - 401 Army General Hospital /ID# 253222
🇬🇷Athens, Attiki, Greece
401 GSNA - 401 Army General Hospital /ID# 253228
🇬🇷Athens, Attiki, Greece
University General Hospital Attikon /ID# 253221
🇬🇷Athens, Attiki, Greece
General Hospital Andreas Syggros /ID# 253220
🇬🇷Athens, Attiki, Greece
Tzaneio general hospital of Piraeus /ID# 253223
🇬🇷Piraeus, Attiki, Greece
Hospital of Skin and Venereal Diseases- Thessaloniki /ID# 253225
🇬🇷Thessaloniki, Evrytania, Greece
Hospital of Skin and Venereal Diseases- Thessaloniki /ID# 253230
🇬🇷Thessaloniki, Evrytania, Greece
Papageorgiou General Hospital /ID# 253226
🇬🇷Thessaloniki, Evrytania, Greece
Naval Hospital of Athens /ID# 253229
🇬🇷Athens, Greece
University General Hospital of Larissa /ID# 254216
🇬🇷Larissa, Greece
Debreceni Egyetem-Klinikai Kozpont /ID# 239949
🇭🇺Debrecen, Hajdu-Bihar, Hungary
Pecsi Tudomanyegyetem Klinikai Kozpont /ID# 239950
🇭🇺Pecs, Nograd, Hungary
Vas Varmegyei Markusovszky Egyetemi Oktatokorhaz /ID# 239951
🇭🇺Szombathely, Vas, Hungary
Semmelweis Egyetem /ID# 239948
🇭🇺Budapest, Hungary
Szegedi Tudományegyetem /ID# 239947
🇭🇺Szeged, Hungary
HaEmek Medical Center /ID# 247834
🇮🇱Afula, H_efa, Israel
Rambam Health Care Campus /ID# 244904
🇮🇱Haifa, H_efa, Israel
Maccabi /ID# 252598
🇮🇱Haifa, H_efa, Israel
The Edith Wolfson Medical Center /ID# 244902
🇮🇱Ashkelon, HaDarom, Israel
Duplicate_Kaplan Medical Center /ID# 244903
🇮🇱Rehovot, HaMerkaz, Israel
Leumit /ID# 260022
🇮🇱Rehovot, HaMerkaz, Israel
ZIV Medical Center /ID# 244908
🇮🇱Safed, HaTsafon, Israel
Sheba Medical Center /ID# 244905
🇮🇱Ramat Gan, Tel-Aviv, Israel
Tel Aviv Sourasky Medical Center /ID# 244907
🇮🇱Tel Aviv, Tel-Aviv, Israel
Shaare Zedek Medical Center /ID# 247833
🇮🇱Jerusalem, Yerushalayim, Israel
Ospedale San Martino /ID# 255081
🇮🇹Genoa, Genova, Italy
IRCCS Ospedale San Raffaele /ID# 255285
🇮🇹Milan, Milano, Italy
AOU Citta della Salute e della Scienza di Torino /ID# 254615
🇮🇹Torino, Piemonte, Italy
AOU San Giovanni e Ruggi Salerno - Presidio Ospedaliero S.M.I. dell'Olmo /ID# 254689
🇮🇹Cava De' Tirreni, Salerno, Italy
A.O.U. Consorziale Policlinico di Bari /ID# 254612
🇮🇹Bari, Italy
AOU Policlinico G. Rodolico - San Marco /ID# 255707
🇮🇹Catania, Italy
AOU Gaetano Martino /ID# 255080
🇮🇹Messina, Italy
Azienda Ospedaliero Universitaria Maggiore della Carita di Novara /ID# 254613
🇮🇹Novara, Italy
Fondazione Policlinico Universitario Campus Bio-Medico /ID# 255283
🇮🇹Roma, Italy
Azienda ULSS 8 Berica /ID# 255011
🇮🇹Vicenza, Italy
Centro de Investigacion Biologica y Terapia Avanzada SC (CIMBYTA) /ID# 243820
🇲🇽Guadalajara, Jalisco, Mexico
Centro Dermatologico Del Country S de Rl de Cv /Id# 243818
🇲🇽Guadalajara, Jalisco, Mexico
Grupo Clinico Catei Sociedad Civil /Id# 243809
🇲🇽Guadalajara, Jalisco, Mexico
Welsh Derm Centro de Especialidades Medicas /Id# 268403
🇲🇽Monterrey, Nuevo Leon, Mexico
Consultorio Medico Privado Alejandra Macias Weinmann /Id# 244159
🇲🇽Monterrey, Nuevo Leon, Mexico
Clinica Dermassad /Id# 264048
🇲🇽San Pedro Garza García, Nuevo Leon, Mexico
Consultorio Medico Privado Cipactli Ariel Navarro Hernandez /Id# 244165
🇲🇽Oaxaca de Juárez, Oaxaca, Mexico
Consultorio Medico Privado Yuri Igor Lopez Carrera /Id# 244164
🇲🇽San Andrés Cholula, Puebla, Mexico
Consultorio Privado Leslie Lourdes Rodriguez /Id# 243819
🇲🇽Mérida, Yucatan, Mexico
Consultorio Medico Privado Desiree Larenas Linnemann /Id# 244150
🇲🇽Ciudad de Mexico, Mexico
Centro Especializado en Diabetes, Obesidad y Prevencion de Enfermedades Cardiova /ID# 243856
🇲🇽Mexico City, Mexico
Neki Servicios Medicos Profesionales S D Rl de Cv /Id# 243817
🇲🇽Toluca, Mexico
Dermoklinika Medical Center /ID# 251249
🇵🇱Lodz, Lodzkie, Poland
Luxderm Specjalistyczny Gabinet Dermatologiczny, /ID# 253106
🇵🇱Lublin, Lubelskie, Poland
Maciej Pastuszczak Indywidualna Praktyka Lekarska /ID# 253105
🇵🇱Cracow, Malopolskie, Poland
Panstwowy Instytut Medyczny MSWiA w Warszawie /ID# 252447
🇵🇱Warszawa, Mazowieckie, Poland
Prywatna Praktyka Lekarska Witold Owczarek /ID# 252448
🇵🇱Warszawa, Mazowieckie, Poland
KSW nr1 w Rzeszowie /ID# 251251
🇵🇱Rzeszow, Podkarpackie, Poland
Chelyabinsk Regional Clinical Dermatovenerologic Dispensary /ID# 248262
🇷🇺Chelyabinsk, Chelyabinskaya Oblast, Russian Federation
Clinical Dermatovenerology Dispensary /ID# 245225
🇷🇺Krasnodar, Krasnodarskiy Kray, Russian Federation
Republican hospital named after V.A. Baranov /ID# 245230
🇷🇺Petrozavodsk, Kurskaya Oblast, Russian Federation
Research and Clinical Center for Hematology, Oncology and Immunology, Ryazan Sta /ID# 245220
🇷🇺Ryazan, Ryazanskaya Oblast, Russian Federation
LLC Scientific Medical Center for General Therapy and Pharmacology /ID# 245229
🇷🇺Stavropol, Stavropol Skiy Kray, Russian Federation
Hospital Universitario Germans Trias i Pujol /ID# 248512
🇪🇸Badalona, Barcelona, Spain
Hospital Universitari de Bellvitge /ID# 248513
🇪🇸L'Hospitalet de Llobregat, Barcelona, Spain
Hospital Universitari Mútua Terrassa /ID# 254292
🇪🇸Terrassa, Barcelona, Spain
Hospital San Pedro /ID# 248538
🇪🇸Logroño, La Rioja, Spain
Hospital Universitario Dr. Negrin /ID# 248533
🇪🇸Las Palmas de Gran Canaria, Las Palmas, Spain
Hospital Santa María del Rosell /ID# 251956
🇪🇸Cartagena, Murcia, Spain
Hospital Universitario Canarias /ID# 251957
🇪🇸San Cristóbal de La Laguna, Santa Cruz De Tenerife, Spain
Hospital Universitario Basurto /ID# 248508
🇪🇸Bilbao, Vizcaya, Spain
Hospital Parc de Salut del Mar /ID# 258675
🇪🇸Barcelona, Spain
Hospital Santa Creu i Sant Pau /ID# 248511
🇪🇸Barcelona, Spain
Hospital Universitario Virgen de las Nieves /ID# 248528
🇪🇸Granada, Spain
Hospital Universitario Clinico San Cecilio /ID# 248530
🇪🇸Granada, Spain
Hospital Juan Ramon Jimenez /ID# 251960
🇪🇸Huelva, Spain
Hospital Universitario de Jaen /ID# 251959
🇪🇸Jaen, Spain
Hospital Universitario Lucus Augusti /ID# 248507
🇪🇸Lugo, Spain
Hospital Universitario Virgen de la Victoria /ID# 248531
🇪🇸Malaga, Spain
Hospital Universitario de Salamanca /ID# 253356
🇪🇸Salamanca, Spain
Hospital Universitario Nuestra Señora de Candelaria /ID# 251961
🇪🇸Santa Cruz de Tenerife, Spain
Hospital Universitario Virgen del Rocio /ID# 248527
🇪🇸Sevilla, Spain
Hospital Clinico Universitario de Valladolid /ID# 253355
🇪🇸Valladolid, Spain
Kantonsspital Aarau AG /ID# 245517
🇨🇭Aarau, Aargau, Switzerland
Dermatology & Skin Care Clinic /ID# 238348
🇨🇭Buochs, Nidwalden, Switzerland
Kantonsspital St. Gallen /ID# 239244
🇨🇭St. Gallen, Sankt Gallen, Switzerland
Haut- und Laserzentrum Weinfelden /ID# 239248
🇨🇭Weinfelden, Telangana, Switzerland
EOC Ospedale Regionale di Bellinzona e Valli /ID# 239246
🇨🇭Bellinzona, Ticino, Switzerland
Basile Darbellay SA /ID# 239245
🇨🇭Orsières, Valais, Switzerland
University Hospital Zurich /ID# 240076
🇨🇭Zurich, Zuerich, Switzerland
Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 244758
🇨🇳Kaohsiung, Keelung, Taiwan
Chung Shan Medical University Hospital /ID# 244757
🇨🇳Taichung, Keelung, Taiwan
National Taiwan University Hospital /ID# 244754
🇨🇳Taipei City, Taipei, Taiwan
Chang Gung Memorial Foundation-Taipei Branch /ID# 244760
🇨🇳Taipei City, Taiwan
Taipei Veterans General Hosp /ID# 244759
🇨🇳Taipei, Taiwan
Linkou Chang Gung Memorial Hospital /ID# 244756
🇨🇳Taoyuan City, Taiwan
New Medical Center Hospital /ID# 245106
🇦🇪Abu Dhabi, United Arab Emirates
Tawam Hospital /ID# 249696
🇦🇪Abu Dhabi, United Arab Emirates
Safa Clinic /ID# 248492
🇦🇪Dubai, United Arab Emirates